Saxenda® Provides Consistent Weight Loss and Improvements in Blood Glucose Control Across BMI Categories After Three Years of Treatment

MUNICH, September 14, 2016 /PRNewswire/ --

This material is intended for global medical media only.

For journalistic assessment and preparation before publication.

Results from a post hoc analysis of the three-year part of the phase 3a SCALE


and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show that

people treated with Saxenda(R) (liraglutide 3 mg) experienced consistent weight loss


improved blood glucose control across baseline body mass index (BMI) categories over


years as compared to placebo treatment. These data were presented today at the 52nd


Meeting of the European Association for the Study of Diabetes (EASD) 2016.

In the trial, adults with prediabetes and obesity or who were overweight with

comorbidities were randomised to receive Saxenda(R) (n=1,505) or placebo (n=749) for


weeks, both as an adjunct to a reduced-calorie diet and increased physical activity.1

"Treating obesity and related comorbidities can be complex and challenging," said

Professor Sten Madsbad, clinical professor at the University of Copenhagen and a SCALE

clinical trial investigator. "It is encouraging to now have three-year data


that, regardless of starting BMI, people in the trial experienced consistent weight


and improvements in several measures of glycaemic control."

As part of this analysis, measures of blood glucose control and the overall safety

profile across baseline BMI categories in people treated with Saxenda(R) vs placebo


assessed. These baseline BMI categories were classified as; overweight: BMI 27-29.9


obesity class 1: BMI 30-34.9 kg/m2, obesity class 2: BMI 35-39.9 kg/m2 and obesity

class 3

and over: BMI greater than or equal to40 kg/m2. People treated with Saxenda(R)


consistent weight loss across all BMI categories: 5.7%, BMI 27-29.9 kg/m2; 6.5%, BMI

30-34.9 kg/m2; 6.2%, BMI 35-39.9 kg/m2; 5.9%, BMI greater than or equal to40 kg/m2

compared to 1.8%, 1.7%, 1.8% and 2.1% in the same categories with placebo treatment.


percentage of individuals who reverted to normal blood glucose levels at 160 weeks on

Saxenda(R) was also similar at: 67%, 67%, 70% and 63%, respectively, in each of the


BMI categories and significantly greater compared to 36%, 34%, 40% and 33%,


with placebo (p

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen